Výsledky vyhledávání - "Y. S. Gladbach"

Akademický článek

Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Autor: L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, H. Murua Escobar

Publikováno v: Cancer Cell International, Vol 20, Iss 1, Pp 1-14 (2020)

Abstract Background The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of t

Externí odkaz: https://doaj.org/article/b57c4052d3ff44699e1ea56403b7ff78

Zobrazit plný text záznamu

Additional file 5 of Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Autor: L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, Escobar, H. Murua

Additional file 5. pathway_components. Abstract of the WNT and BCR signaling pathway and the components.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26b241068b150b386e30e4c957e17cda

Zobrazit plný text záznamu

Additional file 3 of Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Autor: L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, Escobar, H. Murua

Additional file 3. supplement figures. Heatmaps of the top-100 up- and downregulated genes of the biological triplicates.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a7d89cf78c06b6821040ecac07ce0b4

Zobrazit plný text záznamu

Additional file 1 of Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Autor: L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, Escobar, H. Murua

Additional file 1. FACS plots. Plots of apoptotic (Annexin V FITC+ and Propidium iodide-) and necrotic cells (Annexin V FITC+ and Propidium iodide+) detected by flow cytometry analysis at 72h of pro-B ALL cell lines RS4;11 and SEM exposed with AraC,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4924ad06fcb4759c44c3fb4313fc41ea

Zobrazit plný text záznamu

Additional file 2 of Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Autor: L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, Escobar, H. Murua

Additional file 2. supplement tables. Comparison of the differential expression analysis of RS4;11 and SEM exposed with AraC, DEX and IDEL and two drugs combined (AraC+IDEL, DEX+IDEL) for 72 h.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6b213a989556229a31fe249c8e04ac0

Zobrazit plný text záznamu

Additional file 6 of Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines

Autor: L.-M. Sklarz, Y. S. Gladbach, M. Ernst, M. Hamed, C. Roolf, S. Sender, J. Beck, E. Schütz, S. Fischer, S. Struckmann, C. Junghanss, G. Fuellen, Escobar, H. Murua

Additional file 6. pw_ranking_Idel. Pathway ranking of pathways with components mTOR, BTK, AKT, and PI3K.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::976e2598c8bc66e255b98767be85adc4

Zobrazit plný text záznamu

Autor: L-M, Sklarz, Y S, Gladbach, M, Ernst, M, Hamed, C, Roolf, S, Sender, J, Beck, E, Schütz, S, Fischer, S, Struckmann, C, Junghanss, G, Fuellen, H, Murua Escobar

Publikováno v: Cancer Cell International

Background The introduction of combined conventional cytostatics and pathway-specific inhibitors has opened new treatment options for several cancer types including hematologic neoplasia such as leukaemias. As the detailed understanding of the combin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98bf44e035189759dc1406b46dbced4d
https://pubmed.ncbi.nlm.nih.gov/32817744

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání